Abstract
Recently, the complexity and costs of clinical trials have increased dramatically, especially in the area of new drug development. Risk-based monitoring (RBM) has been attracting attention as an efficient and effective trial monitoring approach, which can be applied irrespectively of the trial sponsor, i.e., academic institution or pharmaceutical company. In the RBM paradigm, it is expected that a statistical approach to central monitoring can help improve the effectiveness of on-site monitoring by prioritizing and guiding site visits according to central statistical data checks, as evidenced by examples of actual trial datasets. In this review, several statistical methods for central monitoring are presented. It is important to share knowledge about the role and performance capabilities of statistical methodology among clinical trial team members (i.e., sponsors, investigators, data managers, monitors, and biostatisticians) in order to adopt central statistical monitoring for assessing data quality in the actual clinical trial.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
International conference on harmonization of technical requirements for registration of pharmaceuticals for human use (1996) ICH Harmonized Tripartite guideline—Guideline for Good Clinical Practice—E6(R1). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf. Accessed August 2015
Green SG, Benedetti J, Smith A, et al (2012) Data management and quality control. In: Clinical Trials in Oncology 3rd edn. CRC Press, New York, pp 129–153
Journot V, Pignon JP, Gaultier C et al (2011) Validation of a risk-assessment scale and a risk-adaptive monitoring plan for academic clinical research studies—the pre-optimon study. Contemp Clin Trials 32:16–24
USA Department of Health and Human Services, Food and Drug Administration (2011) Guidance for industry: oversight of clinical investigations—a risk-based approach to monitoring. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM269919.pdf. Accessed Aug 2015
European Medicines Agency (2011) Reflection paper on risk based quality management in clinical trials. EMA/INS/GCP/394194/2011. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500110059.pdf. Accessed Aug 2015
TransCelerate BioPharma Inc. (2013) Position paper: risk-based monitoring methodology. http://www.transceleratebiopharmainc.com/wp-content/uploads/2013/10/TransCelerate-RBM-Position-Paper-FINAL-30MAY2013.pdf Accessed Aug 2015
Venet D, Doffagne E, Burzykowski T et al (2012) A statistical approach to central monitoring of data quality in clinical trials. Clin Trials 9:705–713
Buyse M, George S, Evans S et al (1999) The role of biostatistics in detection and treatment of fraud in clinical trials. Stat Med 18:3435–3451
Evans S (2008) Statistical aspects of the detection of fraud. In: Fraud and misconduct in biomedical research. The Royal Society of Medicine Press Ltd., London, pp 161–176
Buyse M (2014) Centralized statistical monitoring as a way to improve the quality of clinical trials. Applied Clinical Trials. March 24 http://www.appliedclinicaltrialsonline.com/centralized-statistical-monitoring-way-improve-quality-clinical-data
Kirkwood AA, Cox T, Hackshaw A (2013) Application of methods for central statistical monitoring in clinical trials. Clin Trials 10:783–806
Zink R (2014) Risk-based monitoring and fraud detection in clinical trials using JMP and SAS. SAS Institute Inc., Cary, pp 44–47
Lindblad AS, Manukyan Z, Purohit-Sheth T et al (2014) Central site monitoring: results from a test of accuracy in identifying trials and sites failing Food and Drug Administration inspection. Clin Trials 11:205–217
Baigent C, Harrell FE, Buyse M et al (2008) Ensuring trial validity by data quality assurance and diversification of monitoring methods. Clin Trials 5:49–55
O’Kelly M (2004) Using statistical techniques to detect fraud: a test case. Pharm Stat 3:237–246
Taylor RN, McEntegart DJ, Stillman EC (2002) Statistical techniques to detect fraud and other data irregularities in clinical questionnaire data. Drug Inf J 36:115–125
Al-Marzouki S, Evans S, Marchall T et al (2005) Are these data real? Statistical methods for the detection of data fabrication in clinical trials. BMJ 331:267–270
Edwards P, Shakur H, Barnetson L et al (2014) Central and statistical data monitoring in the clinical randomisation of an antifibrinolytic in significant haemorrhage (CRASH-2) trial. Clin Trials 11:336–343
Zink R, Wolfinger R, Mann G (2013) Summarizing the incidence of adverse events using volcano plots and time intervals. Clin Trials 10:398–406
Tsuburaya A, Yoshida K, Kobayashi M et al (2014) Sequential paclitaxel followed by tegafur and uracil (UFT) or S1 versus UFT or S1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. Lancet Oncol 15:886–893
Timmermans C, Doffagne E, Venet D, et al (2015). Using central statistical monitoring to assess data quality and consistency in the stomach cancer adjuvant multi-institutional group trial (SAMIT). (Epub ahead of print). doi: 10.1007/s10120-015-0533-9
Acknowledgments
I would like to thank the Editors for many useful comments and advice. I also I would also especially like to thank Editage (www.editage.jp) for English language editing.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
About this article
Cite this article
Oba, K. Statistical challenges for central monitoring in clinical trials: a review. Int J Clin Oncol 21, 28–37 (2016). https://doi.org/10.1007/s10147-015-0914-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-015-0914-4